Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

BACKGROUND: Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 inhibitor) in colorectal cancer (CRC), however single agent therapeutics are often limited by the development of resistance. METHODS: We compared the an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Cha Len, Cremona, Mattia, Farrelly, Angela, Workman, Julie A., Kennedy, Sean, Aslam, Razia, Carr, Aoife, Madden, Stephen, O’Neill, Brian, Hennessy, Bryan T., Toomey, Sinead
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281467/
https://www.ncbi.nlm.nih.gov/pubmed/37326340
http://dx.doi.org/10.1080/15384047.2023.2223388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281467/
https://www.ncbi.nlm.nih.gov/pubmed/37326340
http://dx.doi.org/10.1080/15384047.2023.2223388

Ejemplares similares